ELI LILLY & Co 4

Director Gabrielle Sulzberger received a small stock-based compensation award in the form of deferred stock units equivalent to about 4.3232 Eli Lilly common shares valued at roughly $1.1K.

On July 20, 2026, director Gabrielle Sulzberger of Eli Lilly & Co elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, resulting in an award of approximately 4.3232 shares (stock units) of common stock valued at about $1,146.90 in total, which will be settled in actual shares following her separation from service; following this award, her deferred and directly held common stock equivalent ownership increased to about 2,999.7188 shares, worth roughly $3.53 million at the current market price.

Filing Facts

CIK

59478

Ticker

LLY

Form

4

Source Type

fda

Accession

0001262388-26-000014

Alert Tier

4